DE102005062055A1 - Diagnostic method to detect hetero-/homozygote expression of marburg I-variant of factor VII-activating protease (FSAP) expression, comprises determining FSAP activity in sample, using differential activity modulator - Google Patents

Abstract

Diagnostic method for the detection of person with genetically conditioned hetero or homozygote expression of the marburg (MR) I-variant of the factor VII-activating protease (FSAP) expression, comprises determining the activity of the FSAP in a sample, in absence or presence of a differential activity modulator, where the differential activity modulator measurement of the FSAP in samples with genetically dependent hetero or homozygote expression of MR-I variant of the FSAP changes in other extent changes as in samples not expressing the MR-I variant of the FSAP.

Description

The The invention is in the field of diagnosis of the Marburg I (MR I) mutation the coagulation factor VII activating protease (FSAP), at about 5 to 10% of Western European population Is found. According to a study by Willeit et al. point heterozygous carriers the FSAP MR I mutation the average of the population a higher one Risk of developing a carotid stenosis [Willeit et al. (2003): Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis. Circulation 107, 667-670]. There the presence of a FSAP MR I mutation is a potential marker for one genetic disposition for the development of atherosclerotic diseases is the reliable Recognition of homozygous or heterozygous carriers of the FSAP MR I mutation especially with regard to individual health care of interest.

The FSAP is a plasmatic serine protease, also called PHBSP (plasma hyaluronan binding serine protease) has been described. The FSAP is present in human plasma in a concentration of about 12 ug / ml and can over Autocatalysis of the single-chain proenzyme (single chain, sc-FSAP) in the active two-chain protease (two chain, tc-FSAP) are transferred. The active protease has several functions or activities. It is known that the FSAP on the one hand has the ability, the blood clotting factor VII as well as single chain plasminogen activators, such as plasminogen activating Prourokinases, such as scuPA (single chain urokinase plasminogen activator) and activate sctPA (single chain tissue plasminogen activator). On the other hand the FSAP over the ability, inactivate the blood coagulation factors V / Va and VIII / VIIIa.

Various test methods for the qualitative or quantitative determination of FSAP, which make use of these biological activities of the FSAP, are available in EP 952 215 A2 described. Another activity of the FSAP, which allows a determination of the active protease and is also described in the aforementioned patent document and in Römisch et al. (1999): The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis 29, 292-299 and in Hunfeld et al. (1999): Detection of a novel plasma serine protease during purification if vitamin K-dependent coagulation factors. FEBS Letters 456, 290-294, is the amidolytic activity of FSAP towards low molecular weight substrates, particularly towards the chromogenic substrate S-2288 (HD-IIe-Pro-Arg-pNA).

In addition to the wild-type sequence of the human FSAP gene, various nucleotide polymorphisms are known, which in two cases also lead to a change in the amino acid sequence ( EP 1 182 258 A1 ). The so-called Marburg I mutation (also polymorphism, allele or variant) results in Gly / Glu amino acid replacement at position 534 of the proenzyme including the signal peptide (Gly / Glu 534) and results in a 50-80% reduction in prourokinase activating activity while the ability to activate Factor VII remains unchanged. Another mutation, the so-called Marburg II (MR II) mutation (also MR II polymorphism, allele or variant) leads to a Glu / Gln amino acid exchange at position 370 of the proenzyme including the signal peptide (Glu / Gln 370). However, the Marburg II mutation has no effect on the prourokinase-activating activity of FSAP.

Identification of individuals who carry at least one copy of the FSAP MR I variant is possible in the art using two different methodological approaches. Reliable detection of Gly / Glu amino acid substitution at position 534 of the proenzyme (Gly / Glu 534) has previously been possible only by sequencing the corresponding coding region in the genomic DNA or mRNA. G / A base replacement in the genomic sequence that can be detected at nucleotide position 1601 of the cDNA forms the genetic cause of the FSAP MR I mutant ( EP 1 182 258 A1 ). Although the DNA sequence analysis provides reliable results, there is a need for test procedures on the part of the routine laboratory that are as inexpensive, fast and safe as possible and which can also be processed automatically on existing diagnostic devices. Predominantly preferred are immunochemical detection or test methods, since they meet the stated criteria and have already found wide use in laboratory diagnostics.

Another method for determining a FSAP MR I mutant is based on the determination of the prourokinase activation potential of FSAP in a sample. For this purpose, a specific antibody, which is unable to distinguish between wild-type FSAP and the known FSAP variants, coupled to a solid phase and incubated with the sample liquid. Upon addition of prourokinase as a FSAP substrate and a chromogenic urokinase substrate, the amount of chromogen reacted is determined as a measure of the prourokinase activating activity of FSAP. Carriers of the Marburg I mutation show 50-80 decreased prourokinase activating activity. Decreased prourokinase activating activity can but also due to a low FSAP concentration in the sample. Therefore, it has hitherto been necessary to determine not only the prourokinase activating activity but also the FSAP antigen concentration of a sample ( EP 1 348 761 A1 ). Monoclonal antibodies are known in the art which allow the immunological detection of FSAP. In EP 1 182 258 A1 describe two monoclonal antibodies derived from the hybridoma cell lines DSM ACC2453 and DSM ACC2454, respectively, obtained after immunization of mice with FSAP protein. Both antibodies bind not only the wild type FSAP protein but also the Marburg I and II variants. Other known FSAP antibodies bind equally to wild type FSAP as well as to the known mutant variants, so that, for example, in a sandwich ELISA the total content of FSAP antigen of a sample is determined (see also DE 100 23 923 A1 ). The prior art therefore teaches that only when a decreased prourokinase activating activity is detected together with an FSAP antigen concentration in the normal range, this is a concrete indication of the presence of a FSAP MR I variant.

Of the The present invention was based on the object further methods to the reliable Diagnosis of MR I mutation or detection of heterozygous or homozygous carriers provide an MRI mutation that allows for FSAP antigen determination to renounce.

The solution This object is to provide the described in the claims inventive method, which make it possible heterozygous or homozygous carriers reliable MR I polymorphism from non-carriers to distinguish. The advantage of the present method, which is the differential modulation of the activity of the FSAP MR I variant too Benefit, consists in a reliable discrimination between carriers and non-carriers the FSAP MR I mutation and, above all, that to an additional Determination of the antigen content of a sample can be dispensed with.

It it has been found that by using suitable activity modulators, so-called differential activity modulators, the activity of the FSAP, in particular the amidolytic activity of FSAP towards low molecular weight Peptide substrates and the plasminogen activator activating activity of FSAP, in Samples from non-carriers of an MR I polymorphism is modulated differently than the activity of FSAP in samples of heterozygous or homozygous carriers of an MR I polymorphism, allowing a distinction between non-carriers and carriers of an MR I polymorphism based on the different degree of modulation of FSAP activity can be taken.

• i) die Aktivität der FSAP sowohl in Proben von Trägern der MR I-Variante der FSAP als auch in Proben von Nichtträgern der MR I-Variante der FSAP inhibiert oder verstärkt, dies aber in unterschiedlichem Ausmaß, oder
• ii) die Aktivität der FSAP in Proben von Trägern der MR I-Variante der FSAP inhibiert und in Proben von Nichtträgern der MR I-Variante verstärkt oder umgekehrt oder
• iii) die Aktivität der FSAP in einem der Probentypen verstärkt oder inhibiert, in dem anderen Probentyp aber keine nennenswerte Veränderung der FSAP-Aktivität bewirkt.

For the purposes of the present invention, a differential activity modulator means a substance or a mixture of substances which either

• i) inhibits or enhances the activity of FSAP both in samples of carriers of the MR I variant of the FSAP and in samples of non-carriers of the MR I variant of the FSAP, but to varying degrees, or
• ii) inhibits the activity of FSAP in samples of carriers of the MR I variant of FSAP and amplifies them in samples of non-carriers of the MR I variant or vice versa or
• iii) enhances or inhibits the activity of FSAP in one of the sample types, but does not cause any appreciable change in FSAP activity in the other sample type.

• a) einen quantitativen Unterschied bei der Inhibition oder Verstärkung der Aktivität der FSAP in Proben von Nichtträgern bzw. Trägern der MR I-Variante der FSAP bewirkt, d. h. die Aktivität der FSAP wird in beiden Probentypen z. B. verstärkt, aber unterschiedlich stark; oder
• b) einen qualitativen Unterschied bei der Modulation der Aktivität der FSAP in Proben von Nichtträgern bzw. Trägern der MR I-Variante der FSAP bewirkt, d. h. in einem der Probentypen wird die Aktivität verstärkt, während im anderen Probentyp die Aktivität inhibiert wird.

Thus, for use as a differential activity modulator, a substance or a mixture of substances is suitable

• a) causes a quantitative difference in the inhibition or enhancement of the activity of the FSAP in samples of non-carriers or carriers of the MR I variant of the FSAP, ie the activity of the FSAP is in both sample types z. B. reinforced, but different degrees; or
• b) causes a qualitative difference in the modulation of the activity of the FSAP in samples of non-carriers or carriers of the MR I variant of the FSAP, ie in one of the sample types the activity is enhanced while in the other sample type the activity is inhibited.

For example is when using aprotinin as a differential activity modulator observed a quantitative difference: the plasminogen activator-activating activity as well as the amidolytic activity of FSAP are in samples from non-carriers stronger inhibited as in samples from carriers the FSAP MR I mutation. Homozygous and heterozygous carriers of Wild-type form or the MR I variant of FSAP can thus be distinguished from each other and be identified with it.

The present invention thus relates to a method for detecting persons with genetically determined heterozygous or homozygous expression of the MR I variant of the FSAP, wherein the change in the activity of the FSAP contained in a sample is determined. For this, the sample with a or several reagents are incubated to allow determination of FSAP activity, and in the course of the reaction a differential activity modulator is added and the change in the response monitored.

Preferably, the change in the plasminogen activator activating activity, particularly preferably the change in the prourokinase activating activity of the FSAP of a biological sample, preferably a blood or plasma sample, determined by the plasminogen activator activating activity or the prourokinase activating activity of the FSAP first measured in the absence of a differential activity modulator based on the turnover kinetics of a plasminogen activator substrate or a urokinase substrate. In the course of the reaction, a differential activity modulator is then added to the reaction mixture and the change in the reaction is monitored. As reagents which are incubated with the sample for determining the plasminogen activator activating activity or the prourokinase activating activity of the FSAP, z. B. solutions or preparations are used which have an inactive plasminogen activator, such as. Prourokinase or sct-PA and solutions or preparations containing a urokinase substrate or a sct-PA substrate. The FSAP-dependent activation of z. B. Prourokinase to urokinase is measured by the reaction or cleavage of the urokinase substrate. Preferred substrates are low molecular weight peptide substrates which have a signal-forming group. The cleavage of the substrate leads to the release of the signal-forming group. The physical or chemical properties of the released signal-producing group are different from the properties of the group coupled to the peptide and can be quantified by suitable methods. As signal-forming group are z. B. the skilled worker known fluorophores, luminophores or chromophores, which can be measured by optical methods, such as luminescence, fluorescence or absorption measurements. Since the signal strength correlates with the amount of cleaved substrate, so the plasminogen activator activating activity of FSAP can be determined. Preferably, a low molecular weight substrate selected from the group S-2444 (Glu-Gly-Arg-para-nitroaniline; Chromogenix Instrumentation Laboratory S.p.A., Milan, Italy.), Pefachrom ^® uPA (Ala-Gly-Arg-para-nitroaniline [Pefa-5221], Pentapharm Ltd., Basel, Switzerland) and Chromozym U (Roche Applied Science, Indianapolis, USA).

In another embodiment will change the amidolytic activity the FSAP of a biological sample, preferably a blood or plasma sample, determined by the amidolytic activity of FSAP initially in Absence of a differential activity modulator based on the turnover kinetics of a low molecular weight FSAP substrate is measured. In the course of the reaction then becomes a differential activity modulator the reaction approach added and the change followed by the reaction. As reagents used to determine the amidolytic activity the FSAP are incubated with the sample, z. B. solutions or Preparations are used which are a low molecular weight FSAP substrate contain. Low molecular weight substrates in the sense of the present invention Invention are peptide substrates consisting of a sequence of 2 to 100, preferably 2 to 50, more preferably 3 to 10 natural or unnatural Amino acids, the additional have a signal-forming group and split by the FSAP become. The cleavage of a low molecular weight substrate leads to Release of the signal-forming group. The physical or chemical properties of the released signal-forming group differ from the properties of those coupled to the peptide Group and can quantified by suitable procedures. When signal-forming group are suitable for. B. known in the art fluorophores, Luminophores or chromophores obtained by optical methods, such as For example, luminescence, fluorescence or absorption measurements can be measured. Because the signal strength correlated with the amount of cleaved substrate, so the amidolytic activity the FSAP will be determined. Preferably, a low molecular weight, chromogenic Substrate from the group Pefa-3297, Pefa-5114, Pefa-5523, Pefa-5773, Pefa-5979, Pefa-3107, Pefa-5329 (all from the Pefachrom series, Pentapharm AG, Basel, Switzerland), S-2288, S-2765, S-2366, S-2238, S-2222, S-2302 (all from the S series, Chromogenix AB, Sweden) [see also Roman et al. (1999) Haemostasis 29, 292-299 and Hunfeld et al. (1999) FEBS Letters 456, 290-294].

In both variants of the activity determination, the measurement of the substrate cleavage reaction can take place over the complete time interval of the reaction up to equilibration. It is also possible that only discrete time intervals are measured, measuring at least one time interval before the addition of the differential activity modulator and at least one time interval after the addition of the differential activity modulator. At a minimum, however, it is necessary to measure at least one time before and at least one time after the addition of the differential activity modulator. To determine the activity, the photometric data, for example spectra or absorption values at specific wavelengths, per se or with respect to a time interval, can be used. If the activity is determined by photometric data with respect to a time interval, ie, the rate of conversion or reaction is recorded, various methods can be used to determine the rate of conversion or reaction. For example, the turnover rate can be determined by means of time-turnover curves become. For time-turnover curves, the cleavage product concentration is plotted against time. To determine the turnover rate, a tangent in the range of the zero-order reaction of the time-turnover curve, usually at the beginning of a measurement of an enzyme reaction, is applied. The slope of the tangent then provides the turnover rate, ie the change in the concentration of the substrate or product in a given time interval (literature: Bisswanger, H., enzyme kinetics: theory and methods, 2nd completely revised edition, VCH Verlagsgesellschaft mbH, 1994, Weinheim , NY, Basel, Cambridge, Tokyo, especially pp. 66-67).

Parameters that are suitable for the evaluation of the turnover kinetics are, for. B. all parameters that describe the reaction kinetics, in particular the reaction kinetics before and after the addition of the differential activity modulator, such. For example, a curve discussion per se, but in particular individual parameters of the reaction kinetics, such as maximum slopes, ie the maximum reaction rates (V _max ), sigmoidity parameters, linearity parameters, the area under the curve or under parts of the curve, etc. Parameters that are suitable for the test evaluation are suitable, for. B. also absolute measurements such. B. Absorbance values measured at a particular time or times when certain absorbance values are reached.

Preferably, the difference or quotient of a test parameter is formed which is determined once in the absence and once in the presence of the activity modulator, ie after its addition to the reaction mixture, to determine the extent of change in FSAP activity. When using an inhibitor, for example, the formation of the difference or the quotient of the maximum reaction rate (V _max ) of substrate _{conversion rate} in the absence of the inhibitor (V _max0 ) and the maximum reaction rate of substrate _conversion rate after addition, ie in the presence of the inhibitor (V _{max inhibitor} ) the differentiation of FSAP-MR I carriers and non-carriers. Other algorithms such as the sum or the product are also suitable if they allow a differentiation.

Under a "sample" is in the sense of Invention to understand the material that the FSAP or the FSAP-MR I variant probably contains. The term "sample" includes biological liquids or tissue, in particular of humans and animals such as blood, plasma, Serum and other body fluids, Excretions or extracts containing the FSAP or FSAP MR I mutant probably included. If necessary, the samples must be pretreated be to the analyte for the detection method accessible to make or disturbing Remove sample components. Such pretreatment of samples may involve the separation and / or lysis of cells, the precipitation, the hydrolysis or denaturation of sample components such as z. As proteins, the centrifugation of samples, treating the Sample with organic solvents like z. For example, alcohols, especially methanol; treating the sample with Detergents. Often the sample is transferred to another, usually aqueous, medium which as far as possible with the verification procedure should not interfere.

In a preferred embodiment The invention relates to a biological sample to be examined, preferably a blood or plasma sample is incubated with a solid phase to which previously a binding partner was coupled with affinity for the FSAP. After washing out the solid phase, the activity of the Binding partner bound FSAP determined.

Preferred are binding partners that bind wild-type FSAP protein with the same affinity as a FSAP protein with MR I mutation. Binding partners that have an affinity for the FSAP and for the enrichment or isolation of FSAP protein from complex protein solutions such. B. plasma samples are, for example, substances from the group heparin, heparan sulfate, dextran sulfate and hyaluronic acid. Also suitable are monoclonal or polyclonal antibodies to FSAP or antibody fragments, such as F (ab ') or F (ab') ₂ fragments. Particular preference is given to monoclonal antibodies which are formed by one of the hybridoma cell lines DSM ACC2453 and DSM ACC2454 deposited with the DSMZ - German Collection of Microorganisms and Cell Cultures GmbH, Mascheroder Weg 1b, 38124 Braunschweig, Germany.

The term "solid phase" for the purposes of this invention includes an article which consists of porous and / or non-porous, generally water-insoluble material and which may have various shapes, such as those of vessels, tubes, microtitration plates, spheres, Microparticles, rods, strips, filter paper or chromatography paper The surface of the solid phase is usually hydrophilic or hydrophilic The solid phase can be made of a wide variety of materials such as inorganic and / or organic materials, synthetic ones , Of naturally occurring and / or of modified naturally occurring materials Examples of solid phase materials are polymers, such as. Cellulose, nitrocellulose, cellulose acetate, polyvinyl chloride, polyacrylamide, crosslinked dextran molecules, agarose, polystyrene, polyethylene, polypropylene, polymethacrylate or nylon; Ceramics, glass, metals, in particular precious metals, including gold and silver; Magnetite, mixtures or combinations thereof, etc. The solid phase may comprise a coating of one or more layers e.g. Example, from proteins, carbohydrates, lipophilic substances, biopolymers, organic polymers or mixtures thereof, for example, to suppress the non-specific binding of sample components to the solid phase or prevent or, for example, to achieve improvements in the suspension stability of particulate solid phases, storage stability, the shaping stability or resistance to UV light, microbes or other destructive agents. Microparticles are often used as solid phase. For the purposes of this invention, the term "microparticles" is to be understood as meaning particles having an approximate diameter of at least 20 nm and not more than 20 μm, usually between 40 nm and 10 μm, preferably between 0.1 and 10 μm, particularly preferably between 0.1 and 5 μm, more preferably between 0.15 and 2 μm The microparticles may be regularly or irregularly shaped and may represent spheres, spheroids, spheres with more or less large cavities or pores They may consist of a porous or non-porous, a swellable or non-swellable material In principle, the microparticles may have any density The microparticles may consist of several layers, such as the so-called "microparticles""Core-and-shell" particles with one core and one or more enveloping layers. The term microparticles includes, for example, dye crystals, metal sols, silica particles, glass particles, magnetic particles, polymer particles, oil drops, lipid particles, dextran and protein aggregates, particles consisting of polymer material, in particular substituted polyethylenes, latex particles, for example. Example of polystyrene, acrylic acid polymers, methacrylic acid polymers, acrylonitrile polymers, acrylonitrile-butadiene-styrene, polyvinyl acetate acrylate, polyvinylpyridine, vinyl chloride acrylate. Of particular interest are particles having reactive groups on their surface, such as carboxyl, amino or aldehyde groups, which have a covalent bond e.g. B. of binding partners to the latex particles allow.

In order to determine whether a substance or a combination of substances is suitable for use as a differential activity modulator in the context of the present invention, the following procedure can be followed:
The influence of the substance or combination of substances to be tested on the plasminogen activator activating activity of the FSAP is determined with samples known to contain the FSAP-MR I variant and with samples known not to be the FSAP-MR I variant but contain the wild type FSAP form. For example, these may be samples from one or more individuals whose FSAP genotype is known. In addition, samples containing a defined amount of FSAP wild-type protein or FSAP MR I protein can be used. The FSAP protein or the FSAP MR I protein, which can be used for the preparation of such a sample can, for. B. be enriched or isolated from human biological material or be prepared recombinant or transgenic. Methods for enrichment, isolation, production or stabilization of FSAP protein are e.g. In the documents EP 1 226 829 A2 . EP 1 074 615 A1 and EP 1 074 616 A1 described.

The plasminogen activator activating activity of FSAP contained in the various samples is then determined in the absence as well as in the presence of the substance to be tested. The substance or the combination of substances to be tested for their suitability as a differential activity modulator are used here in at least one concentration, but preferably in different concentrations, as exemplified by aprotinin in 1 and 2 is shown.

The Extent of change the plasminogen activator activating activity of the FSAP of samples with the FSAP MR I variant versus samples containing the FSAP MR I variant not included, but activity show the FSAP wild type form, allows the identification of substances or combinations of substances used as differential activity modulators can be used. Here you can This identifies substances as differential activity modulators be that you both the activity of the FSAP MR I variant as also the activity inhibit or enhance the wild-type FSAP, but with different Extent. But a substance is also a differential activity modulator, if they have the activity inhibits the FSAP MR I variant and enhances the activity of the FSAP wild-type form or vice versa.

Initial investigations as to whether substances are suitable as differential modulators are carried out with a comparatively small number of samples, for example with at least one sample each with and without FSAP-MR I variant, but preferably with two to ten samples each. Substances, this a significant, preferably a statistically significant distinction of samples with FSAP wild type and FSAP-MR I can be validated by further studies with larger numbers of samples.

Preferably be for the further validation of substances or combinations of substances used the tests with samples of persons of known genotype, to get realistic information about the capacity of the test, the presence or absence of one Determine FSAP MR I variant with sufficient diagnostic specificity and sensitivity. The number of samples to be examined of such a phase I Study hangs of the expected test accuracy and the ratio of Number of samples with and without FSAP-MR I variant from [Obuchowski, N.A. et al. (2004) ROC Curves in Clinical Chemistry: Uses, Misuses and Possible Solutions, Clinical Chemistry, 50: 7, 1118-1125]. With almost perfect test accuracy and a ratio of Samples with and without FSAP MR I variant are equal to one each ten samples sufficient to obtain statistically significant values. The number of samples increased with increasing and decreasing ratio of samples with and without FSAP-MR I variant and with decreasing test accuracy. Here it is, for example necessary to examine more than one hundred samples each.

The investigation of substances or combinations of substances with regard to their suitability as differential activity modulators can, for example, be carried out by determining the prourokinase-activating activity of the FSAP in the presence and absence of these substances, if appropriate in various concentrations. For example, as in Example 1, solid phase-associated binding partners having affinity for the FSAP, in particular an anti-FSAP antibody formed by the hybridoma cell line DSM ACC2453, are used and an activity assay as described in Example 1 is performed. The differentiation between carriers and non-carriers of the FSAP MR I variant is determined by the formation of a quotient between V _{max of} the reaction kinetics of a sample without additive (V _max0 ) and with added substance (V _{max substance} ).

Analogous Can be traded when substances or combinations of substances in terms of their suitability as differential activity modulators the amidolytic activity the FSAP should be investigated. A test method for determination the amidolytic activity The FSAP, as described in Example 2, may be used once in the absence and once in the presence of the substance to be examined.

• a) Ionen (Anionen wie Chlorid, Carbonat, Sulfat, Phosphat etc. oder Kationen wie Natrium, Lithium, Ammonium, Magnesium, Calcium, Mangan etc.);
• b) Chelatoren wie Ethylendiamintetraacetat (EDTA), Ethylen-Glycol-Bis(β-Aminoethylether)-N,N,N,N-Tetraacetat, Citrat etc.;
• c) Detergenzien wie Natriumdodecylsulfat (SDS), Triton^® X 100, Tween^® etc.;
• d) redoxaktive Substanzen wie Dithioerythrol, Dithiothreitol, β-Mercaptoethanol, Glutathion, Liponsäure, Vitamin C, Vitamin E etc.;
• e) Nukleinsäuren, insbesondere Aptamere;
• f) Antikörper;
• g) Proteine, Peptide und Oligopeptide wie beispielsweise Antithrombin III, C1-Esterase-Inhibitor, tissue factor pathway inhibitor (TFPI), Heparincofaktor II, alpha2-Makroglobulin, alpha2-Antiplasmin, Inter-alpha-Trypsin-Inhibitior, alpha1-Antitrypsin, alpha1-Antichymotrypsin, Plasminogenaktivator Inhibitor Typ 2 (PAI-2), Plasminogenaktivator Inhibitor Typ 3 (PAI-3), Kininogen, hochmolekulares Kininogen (HMWK) etc.;
• h) synthetische Serinprotease-Inhibitoren wie FOY-305 [N,N-Dimethylcarbamoylmethyl, 4-(4-guanidinobenzoyloxy)-Phenylacetat] methansulfat] und entsprechende Derivate;
• i) niedermolekulare Protease-Inhibitoren wie FOIPAN (Camostat Mesilate);

Substance classes that are particularly suitable for testing for their suitability as differential activity modulators of FSAP activity include:

• a) ions (anions such as chloride, carbonate, sulfate, phosphate etc. or cations such as sodium, lithium, ammonium, magnesium, calcium, manganese, etc.);
• b) chelators such as ethylenediamine tetraacetate (EDTA), ethylene glycol bis (β-aminoethyl ether) -N, N, N, N-tetraacetate, citrate, etc .;
• c) detergents such as sodium dodecyl sulfate (SDS), Triton ^® X 100, Tween ^® etc .;
• d) redox-active substances such as dithioerythrol, dithiothreitol, β-mercaptoethanol, glutathione, lipoic acid, vitamin C, vitamin E, etc .;
• e) nucleic acids, in particular aptamers;
• f) antibodies;
• g) Proteins, peptides and oligopeptides such as antithrombin III, C1-esterase inhibitor, tissue factor pathway inhibitor (TFPI), heparin cofactor II, alpha2-macroglobulin, alpha2-antiplasmin, inter-alpha-trypsin inhibitor, alpha1-antitrypsin, alpha1 Antichymotrypsin, plasminogen activator type 2 inhibitor (PAI-2), plasminogen activator type 3 inhibitor (PAI-3), kininogen, high molecular weight kininogen (HMWK), etc .;
• h) synthetic serine protease inhibitors such as FOY-305 [N, N-dimethylcarbamoylmethyl, 4- (4-guanidinobenzoyloxy) phenylacetate] methanesulfate] and corresponding derivatives;
• i) low molecular weight protease inhibitors such as FOIPAN (Camostat Mesilate);

One preferred differential activity modulator of FSAP activity for use in a method according to the invention is aprotinin.

characters

1 Figure 4 shows the inhibition of prourokinase activating activity of FSAP in the presence of aprotinin detected for a plasma sample of a non-carrier (wild-type).

2 Figure 4 shows the inhibition of prourokinase activating activity of FSAP in the presence of aprotinin determined for a plasma sample of a heterozygous carrier of the MR I polymorphism.

3 Figure 4 shows the inhibition of amidolytic activity of FSAP in the presence of aprotinin detected for a sample of plasma pool of non-carriers of the FSAP MR I mutation (wild-type).

4 Figure 4 shows the inhibition of amidolytic activity of FSAP in the presence of aprotinin detected for a plasma sample of a heterozygous carrier of the MR I polymorphism.

The The example described below serves as an example of illumination individual aspects of this invention and is not intended to be limiting understand:

example 1

determination the prourokinase activating activity of FSAP in presence and in the absence of the differential activity modulator aprotinin

As a solid phase-associated binding partner with affinity for the FSAP, an anti-FSAP antibody formed by the hybridoma cell line DSM ACC2453 was used. To carry out the heterogeneous detection method, microtiter plates (MTPs) made of polystyrene were used as the solid phase. Anti-FSAP antibody in 50 mM NaHCO ₃ , pH 8.2 at a coating volume of 120 μl per well of MTP and a coating concentration of 20 μg of antibody per ml was associated with the polystyrene solid phase overnight at room temperature. Unbound antibodies were removed by washing three times with 50 mM Tris / HCl buffer, pH 7.2.

In the wells in each case 100 .mu.l of a (to be determined plasma sample in a dilution of 1:70 in sample buffer 150 mM sodium citrate, pH 6.0 with 150 mM NaCl, 100 mM arginine, 1% bovine serum albumin, 0.1% Tween ^® 80, 100 IU heparin / ml). After incubation at +37 ° C for one hour, unbound components were by washing three times with 50 mM sodium phosphate-buffered isotonic saline, 0.02% Tween ^® 20, pH 7.4 removed.

• a) 30 μl Testpuffer I (50 mM Tris/HCl, pH 7,2 mit 150 mM NaCl, 0,2 % Tween^® 80, 15 mM CaCl₂ und 50 I.E./ml Heparin) oder
• b) 30 μl Testpuffer I, der zusätzlich Aprotinin in einer solchen Konzentration enthielt, dass eine finale Konzentration von 0,055 KIE/ml Aprotinin im
• Reaktionsansatz erzielt wurde (1 U = 1 Kallikrein Inhibierende Einheiten [KIE)]; Aprotinin aus Rinderlunge, Sigma-Aldrich Laborchemikalien GmbH, Seelze, Deutschland)

und jeweils 50 μl rProurokinase (Landing Biotech Inc., Brighton, MA, USA; 5 μg/ml in Testpuffer I) und jeweils 50 μl des chromogenen Substrates S-2444 (0,6 mM) in Testpuffer II (100 mM Tris/HCl, 150 mM NaCl, 0,1 % Tween^® 80, pH 8,2) in eine Testvertiefung gegeben und bei +37 °C inkubiert. Die Absorption eines Reaktionsansatzes wurde bei 405 nm über 60 Minuten aufgenommen. Die Ergebnisse sind in Tabelle 1 zusammengefasst. Eine Differenzierung zwischen Trägern und Nichtträgern der FSAP MR I-Variante ist möglich durch die Bildung eines Ratios (Quotienten) zwischen V_max der Reaktionskinetik einer Probe ohne Aprotininzusatz (V_max0) und mit Aprotininzusatz (V_{max Aprotinin}). Hierfür gilt: FSAP-Wildtyp-Vmax0/FSAP-Wildtyp-Vmax Aprotinin > FSAP-MR I-Vmax0/FSAP-MR I-Vmax Aprotinin. To determine the prourokinase activating activity of the FSAP, after removal of the sample and washing out of the solid phase

• a) 30 ul assay buffer I (50 mM Tris / HCl, pH 7.2 with 150 mM NaCl, 0.2% Tween ^® 80, 15 mM CaCl ₂ and 50 IU / ml heparin) or
• b) 30 μl of assay buffer I, which additionally contained aprotinin in a concentration such that a final concentration of 0.055 KIU / ml aprotinin in
• Reaction rate was achieved (1 U = 1 kallikrein inhibitory units [KIE]]; Aprotinin from bovine lung, Sigma-Aldrich Laborchemikalien GmbH, Seelze, Germany)

and 50 μl each of rProurokinase (Landing Biotech Inc., Brighton, MA, USA; 5 μg / ml in assay buffer I) and 50 μl each of chromogenic substrate S-2444 (0.6 mM) in assay buffer II (100 mM Tris / HCl , 150 mM NaCl, 0.1% Tween ^® 80, pH 8.2) in a test well and incubated at + 37 ° C. The absorbance of a reaction mixture was recorded at 405 nm for 60 minutes. The results are summarized in Table 1. Differentiation between carriers and non-carriers of the FSAP MR I variant is possible by forming a ratio (ratio) between V _{max of} the reaction kinetics of a sample without added aprotinin (V _max0 ) and with aprotinin (V _{max aprotinin} ). For this applies: FSAP wild-type V max0 / FSAP wild-type V max aprotinin > FSAP MR IV max0 / FSAP MR IV max aprotinin ,

In addition, FSAP _MRI samples (MR I) show a significantly lower difference between V _max0 and V _{max aprotinin} than FSAP wild-type (WT) _probes (see Table 1). The mean value of the three individual determinations is shown in the column MW.

Table 1

The 1 and 2 show the different reaction kinetics of the reaction of S-2444, ie the prourokinase-activating activity of FSAP. 1 shows the reaction kinetics, which were determined for a plasma sample of a non-carrier without or with the addition of aprotinin (0.036 and 0.055 KIE / ml, final aprotinin concentration). 0.036 KIE / ml aprotinin corresponds to an aprotinin dilution of 1: 30,000 and 0.055 KIE / ml of an aprotinin dilution of 1: 20,000. 2 shows the reaction kinetics, which were determined for a plasma sample of a heterozygous carrier of the FSAP-MR I variant without or with the addition of aprotinin (0.036 and 0.055 KIE / ml final aprotinin concentration). It can be clearly seen that the prourokinase-activating activity of FSAP in the non-carrier sample in the presence of aprotinin is significantly more inhibited than the prourokinase-activating activity of FSAP in the heterozygous carrier sample.

Instead of of aprotinin can contain other substances or mixtures of substances in Test Buffer I. and so on their suitability as differential activity modulators be tested.

Example 2

Determination of amidolytic activity the FSAP opposite the low molecular weight chromogenic peptide substrate S-2288 in the presence and in the absence of the differential activity modulator aprotinin

As a solid phase-associated binding partner with affinity for the FSAP, an anti-FSAP antibody formed by the hybridoma cell line DSM ACC2453 was used. To carry out the heterogeneous detection method, microtiter plates (MTPs) made of polystyrene were used as the solid phase. Anti-FSAP antibodies in 50 mM NaHCO ₃ , pH 8.2 at a coating volume of 120 μl per well of the MTP and a coating concentration of 20 μg of antibody per ml were associated with the polystyrene solid phase overnight at room temperature. Unbound antibodies were removed by washing three times with 50 mM Tris / HCl buffer, pH 7.2. In the wells in each case 100 .mu.l of a (to be determined plasma sample in a dilution of 1:50 in sample buffer 150 mM sodium citrate, pH 6.0 with 150 mM NaCl, 100 mM arginine, 1% bovine serum albumin, 0.1% Tween ^® 80, 100 IU heparin / ml). After incubation at + 37 ° C for one hour, unbound material was removed by washing three times with 50 mM sodium phosphate-buffered isotonic saline, 0.02% Tween ^® 20, pH 7.4.

• a) 30 μl Testpuffer I (50 mM Tris/HCl, pH 6,0 mit 150 mM NaCl, 0,2 % Tween^® 80, 15 mM CaCl₂ und 50 I.E./ml Heparin) oder
• b) 30 μl Testpuffer I, der zusätzlich Aprotinin in einer solchen Konzentration enthielt, dass eine finale Konzentration von 0,055 KIE/ml Aprotinin im Reaktionsansatz erzielt wurde (1 U = 1 Kallikrein Inhibierende Einheiten [KIE)]; Aprotinin aus Rinderlunge, Sigma-Aldrich Laborchemikalien GmbH, Seelze, Deutschland),

und jeweils 80 μl des chromogenen Substrates S-2288 (1,5 mM/L; Chromogenix Instrumentation Laboratory S. p. A., Milano, Italien) in Testpuffer II (100 mM Tris, 150 mM NaCl, 0,1 % Tween 80, pH 8,2) in die Testvertiefung gegeben und für eine Stunde bei +37°C inkubiert. Die Absorption der Reaktionsansätze wurde kontinuierlich bei einer Wellenlänge von 405 nm gemessen. Die Ergebnisse sind in Tabelle 2 zusammengefasst. Eine Differenzierung zwischen Trägern und Nichtträgern der FSAP MR I-Variante ist möglich durch die Bildung eines Ratios (Quotienten) zwischen V_max der Reaktionskinetik einer Probe ohne Aprotininzusatz (V_max0) Und mit Aprotininzusatz (V_{max Aprotinin}). Hierfür gilt: FSAP-Wildtyp-Vmax0/FSAP-Wildtyp-Vmax Aprotinin > FSAP-MR I-Vmax0/FSAP-MR I-Vmax Aprotinin. To determine the amidolytic activity of the FSAP, after removal of the sample and washing out of the solid phase

• a) 30 ul of assay buffer I (50 mM Tris / HCl, pH 6.0 with 150 mM NaCl, 0.2% Tween ^® 80, 15 mM CaCl ₂ and 50 IU / ml heparin) or
• b) 30 μl of assay buffer I, which additionally contained aprotinin in a concentration such that a final concentration of 0.055 KIE / ml aprotinin was achieved in the reaction mixture (1 U = 1 kallikrein inhibiting units [KIE]]; Aprotinin from bovine lung, Sigma-Aldrich Laboratory Chemicals GmbH, Seelze, Germany),

and 80 μl each of chromogenic substrate S-2288 (1.5 mM / L, Chromogenix Instrumentation Laboratory S.p.A., Milano, Italy) in assay buffer II (100 mM Tris, 150 mM NaCl, 0.1% Tween 80 , pH 8.2) in the test well and incubated for one hour at + 37 ° C. The absorption of the reaction mixtures was conti measured at a wavelength of 405 nm. The results are summarized in Table 2. Differentiation between carriers and non-carriers of the FSAP MR I variant is possible by forming a ratio (ratio) between V _{max of} the reaction kinetics of a sample without added aprotinin (V _max0 ) and with aprotinin (V _{max aprotinin} ). For this applies: FSAP wild-type V max0 / FSAP wild-type V max aprotinin > FSAP MR IV max0 / FSAP MR IV max aprotinin ,

In addition, FSAP _MRI samples (MR I) show a significantly lower difference between V _max0 and V _{max aprotinin} than FSAP wild-type (WT) _probes (see Table 2). The mean value of the three individual determinations is shown in the column MW.

Instead of of aprotinin can contain other substances or mixtures of substances in Test Buffer I. and so on their suitability as differential activity modulators be tested.

Table 2

The 3 and 4 show the different reaction kinetics of the reaction of S-2288, ie the amidolytic activity of FSAP. 3 shows the reaction kinetics, which were determined for a plasma sample of a non-carrier of the MR I mutation without or with the addition of aprotinin (0.036 and 0.055 KIE / ml, final aprotinin concentration). 0.036 KIE / ml aprotinin corresponds to an aprotinin dilution of 1: 30,000 and 0.055 KIE / ml of an aprotinin dilution of 1: 20,000. 4 shows the reaction kinetics, which were determined for a plasma sample of a heterozygous carrier of the FSAP-MR I variant without or with the addition of aprotinin (0.036 and 0.055 KIE / ml final aprotinin concentration). It can be clearly seen that the amidolytic activity of FSAP in the non-carrier sample in the presence of aprotinin is significantly more inhibited than the amidolytic activity of FSAP in the heterozygous carrier sample.

Claims (10)

A diagnostic method for the detection of persons with genetically determined heterozygous or homozygous expression of the MR I variant of factor VII activating protease (FSAP), in which the activity of the FSAP contained in a sample is determined by the sample with one or more reagents is incubated, characterized in that the reaction of the sample with the reagents is started and in the course of the reaction, a differential activity modulator is added and the change in the reaction is followed. A diagnostic method according to claim 1, wherein the amidolytic activity the FSAP contained in a sample is determined by the sample is incubated with a low molecular weight substrate. A diagnostic method according to claim 1, wherein the plasminogen activator activating activity of FSAP present in a sample is determined by adding the sample with a single chain-type activator and a plaminogen activator substrate. A diagnostic method according to claim 3, wherein the prourokinase-activating activity of FSAP present in a sample is determined by the sample with prourokinase and a urokinase substrate is incubated. Diagnostic method according to one of claims 1 to 4, in which the sample was incubated with a solid phase to the previously a binding partner was coupled with affinity for the FSAP and after washing out the solid phase, the activity of the binding partner bound FSAP is determined. A diagnostic method according to claim 5, wherein the binding partner with affinity for the FSAP an anti-FSAP antibody or a fragment thereof. A diagnostic method according to claim 6, wherein the anti-FSAP antibody is a monoclonal antibody that of one of the hybridoma cell lines DSM ACC2453 and DSM ACC2454 is formed. A diagnostic method according to claim 5, wherein the binding partner with affinity for the FSAP a substance from the group heparin, heparan sulfate, dextran sulfate and hyaluronic acid is. Method according to one of claims 1 to 8, wherein as a differential activity modulator Aprotinin is used. Method according to one of claims 1 to 8, wherein as a differential activity modulator a monoclonal or polyclonal anti-FSAP antibody is used becomes.